Zeon Corporation Invests in Digital Chemistry Pioneer Chemify to Accelerate Automated Drug Discovery
核心洞察
Zeon Corporation (搜索) has made a strategic investment in Chemify (搜索), a UK-based digital chemistry company that automates molecular design and synthesis for medicines and advanced materials.
Chemify (搜索)'s Chemputation (搜索) technology enables fully automated Design-Make-Test-Analyze cycles, potentially reducing compound synthesis time by 10-fold compared to traditional methods.
The partnership aims to leverage Chemify (搜索)'s robotic systems and automated chemistry facility in Glasgow to accelerate development of novel compounds addressing global health challenges.
Zeon Corporation (搜索), through its venture capital arm Zeon Ventures Inc. (搜索), has made a strategic investment in Chemify (搜索) Ltd., a UK growth-stage company pioneering digital chemistry for accelerating the design, discovery, and synthesis of novel molecules for medicines and advanced materials. The partnership represents a significant step forward in automating pharmaceutical research and development processes.
Revolutionary Chemputation Technology
Chemify (搜索) stands at the forefront of digitizing and automating the entire chemical discovery and synthesis process through its proprietary Chemputation (搜索) technology. This innovative platform translates target molecules into proven chemical code that runs directly on the company's robotic systems, enabling fully automated Design-Make-Test-Analyze cycles. By automating the end-to-end cycle from molecular design to synthesis and analysis, Chemify can access novel chemical space and potentially achieve a 10-fold reduction in the time required from initial conception to compound synthesis.
The company has established its first Chemifarm, a fully automated chemistry facility in Glasgow, Scotland, described as one of the world's most advanced laboratories for molecular design and synthesis. This facility enables automated synthesis and rapid iteration for the discovery of novel small molecules, moving from code to compound faster than ever before, fueling innovations in advanced materials and pharmaceutical applications.
Strategic Partnership Goals
According to the companies, the development of novel, makeable molecules is essential to helping address global challenges in human health, energy conservation, and environmental sustainability. Zeon Corporation (搜索) has positioned itself as an early adopter of digital transformation in chemical research, seeking to redefine the future of R&D since the field's infancy.
Through this investment and partnership, Zeon aims to leverage Chemify (搜索)'s cutting-edge technology to further accelerate its digital chemistry initiatives and drive the creation of new materials and compounds that can provide meaningful solutions to society's most pressing challenges.
Zeon's Growth Strategy
The investment aligns with Zeon Corporation (搜索)'s STAGE30 medium-term management plan, which aims to raise the sales ratio of four growth areas - Mobility, Healthcare and Life Science, Telecommunications and Green Transformation - to 48% of total sales by fiscal 2028. The company has committed to continuing its contribution to a 'sustainable planet' and 'safe and comfortable society' by investing in and supporting innovative companies and developing new materials that can transform various fields and industries.
Zeon Ventures Inc. (搜索), the company's California-based venture capital arm led by representative Kazuhiro Takahashi, operates with an investment scale of US$50 million and focuses on startup companies and related activities.
Company Profiles
Chemify (搜索) Ltd., led by representative Lee Cronin and headquartered at 11 Chapel Lane, Glasgow, specializes in molecular design, discovery and automated synthesis. The company's innovative approach to digital chemistry represents a paradigm shift in how pharmaceutical and materials research can be conducted, offering unprecedented speed and efficiency in compound development.